Therapeutic Effects of Resveratrol in a Mouse Model of LPS and Cigarette Smoke-Induced COPD

Inflammation. 2016 Dec;39(6):1949-1959. doi: 10.1007/s10753-016-0430-3.

Abstract

This study was designed to examine whether resveratrol exerts the protective effects on LPS and cigarette smoke (LC)-induced COPD in a murine model. In lung histopathological studies, H&E, Masson's trichrome, and AB-PAS staining were performed. The cytokines (IL-6, IL-17, TGF-β, and TNF-α) and inflammatory cells in BALF were determined. The Beclin1 level in the lungs of mouse was analyzed. Compared with the LC-induced mouse, the level of inflammatory cytokines (IL-17, IL-6, TNF-α, and TGF-β) of the BALF in the resveratrol + cigarette smoke-treated mouse had obviously decreased. Histological examination of the lung tissue revealed that the resveratrol treatment attenuated the fibrotic response and mucus hypersecretion. In addition, resveratrol inhibited the expression of the Beclin1 protein in mouse lungs. The presented findings collectively suggest that resveratrol has a therapeutic effect on mouse LC-induced COPD, and its mechanism of action might be related to reducing the production of the Beclin1 protein.

Keywords: COPD; beclin1; mucus hypersecretion; resveratrol.

MeSH terms

  • Animals
  • Beclin-1 / biosynthesis
  • Beclin-1 / drug effects
  • Bronchoalveolar Lavage Fluid / chemistry
  • Cytokines / drug effects
  • Lipopolysaccharides / adverse effects
  • Lung / metabolism
  • Lung / pathology
  • Mice
  • Mucus / drug effects
  • Mucus / metabolism
  • Pulmonary Disease, Chronic Obstructive / chemically induced
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / etiology*
  • Pulmonary Fibrosis / drug therapy
  • Resveratrol
  • Smoke / adverse effects*
  • Stilbenes / pharmacology
  • Stilbenes / therapeutic use*

Substances

  • Beclin-1
  • Becn1 protein, mouse
  • Cytokines
  • Lipopolysaccharides
  • Smoke
  • Stilbenes
  • Resveratrol